Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE vs BACITRACIN-NEOMYCIN-POLYMYXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of m RNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.
Treatment of superficial ocular infections caused by susceptible organisms,Reduction of inflammation in corticosteroid-responsive ocular conditions,Off-label: treatment of otitis externa (otic preparations)
Treatment of superficial bacterial infections of the skin and mucous membranes (e.g., wounds, burns, impetigo, folliculitis),Prophylaxis of minor skin abrasions and wounds to prevent infection,Off-label: Use in conjunctival irrigation or ophthalmic infections (as combination ophthalmic preparations)
Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.
Apply topically to affected area 2-5 times daily.
Bacitracin: 1.5 h (systemic) but clinically irrelevant as topical. Neomycin: 2-3 h (systemic). Polymyxin B: 4.5-6 h (systemic). Hydrocortisone acetate: 1.5-2.5 h (plasma); clinical effect outlasts serum half-life due to intracellular activity.
Bacitracin: 1.5 hours (prolonged in renal impairment); Neomycin: 2-3 hours (accumulates with renal dysfunction); Polymyxin B: 6-9 hours (increased in renal impairment).
Bacitracin: not metabolized, excreted renally; neomycin: minimally metabolized, excreted renally; polymyxin B: metabolism unknown, excreted renally; hydrocortisone acetate: hepatic metabolism via CYP3A4, glucuronidation, sulfation.
Not extensively metabolized. Systemic absorption from topical application is minimal; absorbed drug may undergo hepatic metabolism or be excreted renally unchanged.
Bacitracin: renal (minimal systemic absorption; eliminated unchanged in urine if absorbed). Neomycin: renal (90-95% excreted unchanged in urine after systemic absorption). Polymyxin B: renal (60% excreted unchanged over 24h; prolonged elimination in renal impairment). Hydrocortisone acetate: hepatic metabolism (glucuronidation, sulfation) and renal excretion of metabolites.
Bacitracin: primarily renal (>90% unchanged); Neomycin: renal (30-50% unchanged) with non-renal clearance; Polymyxin: renal excretion of parent drug (60-80% unchanged) with some biliary and fecal elimination.
Bacitracin: ~10% (albumin). Neomycin: <30% (albumin). Polymyxin B: 55-60% (albumin, alpha-1-acid glycoprotein). Hydrocortisone acetate: 90-95% (corticosteroid-binding globulin, albumin).
Bacitracin: <10% bound to plasma proteins; Neomycin: 0-30% bound; Polymyxin B: 50-70% bound, primarily to alpha-1-acid glycoprotein and lipoproteins.
Bacitracin: 0.3 L/kg (minimal distribution). Neomycin: 0.2-0.4 L/kg (extracellular fluid). Polymyxin B: 0.6-0.8 L/kg (extensively bound to cell membranes). Hydrocortisone acetate: 0.3-0.6 L/kg (total body water).
Bacitracin: 0.3 L/kg (confined to extracellular fluid); Neomycin: 0.2-0.3 L/kg (low tissue penetration except renal cortex); Polymyxin B: 0.7-1.0 L/kg (extensive tissue binding).
Topical/otic/ophthalmic: negligible systemic absorption (<1% for bacitracin, neomycin, polymyxin B; <5% for hydrocortisone acetate). Oral: not applicable (not administered systemically).
Oral: negligible (<1%) for all three components; topical: minimal systemic absorption via intact skin (<0.5%); ophthalmic/otic: minimal absorption via mucosal surfaces.
No systemic absorption anticipated with topical, ophthalmic, or otic use; however, for extensive topical application, caution in renal impairment due to neomycin and polymyxin B. GFR <30 m L/min: monitor for nephrotoxicity; reduce frequency if topical use over large areas.
No systemic absorption; no dosage adjustment required.
No specific adjustment required for topical, ophthalmic, or otic use. Hydrocortisone acetate is hepatically metabolized; however, systemic exposure is minimal. Child-Pugh Class C: use with caution if applied to large areas or broken skin.
No systemic absorption; no dosage adjustment required.
Children: Apply a thin layer to affected area 3-4 times daily. Ophthalmic: Use same as adult dose. Otic: Infants and children: 3 drops into affected ear(s) 3-4 times daily. Safety and efficacy in neonates not established.
Apply topically to affected area 2-5 times daily; same as adult dose.
No specific dose adjustment required. Use with caution in elderly with impaired renal or hepatic function, especially if applied to large areas. Monitor for skin atrophy and systemic effects of hydrocortisone with prolonged use.
Apply topically to affected area 2-5 times daily; same as adult dose.
None.
Not applicable for topical formulations. However, systemic use of bacitracin (rare) may cause nephrotoxicity and anaphylactic reactions. Neomycin may cause ototoxicity and nephrotoxicity with systemic absorption.
Prolonged use may lead to secondary infections (e.g., fungal) or hypersensitivity; ophthalmic use may cause increased intraocular pressure, cataract formation, and delayed wound healing; avoid use in patients with epithelial herpes simplex keratitis; systemic absorption may cause nephrotoxicity and ototoxicity (especially neomycin); use with caution in hepatic impairment.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Topical use may cause allergic contact dermatitis, especially with neomycin.,Avoid application to large areas, open wounds, or damaged skin due to potential systemic absorption and toxicity.,Use with caution in patients with renal impairment or pre-existing hearing loss (neomycin component).,Ototoxicity and nephrotoxicity may occur if significant systemic absorption occurs.
Hypersensitivity to any component; ocular tuberculosis, viral infections of the cornea (e.g., herpes simplex keratitis), fungal diseases of the eye; untreated purulent infections; use in ears with tympanic membrane perforation (otic preparations).
Hypersensitivity to any component (bacitracin, neomycin, polymyxin B) or other aminoglycosides/polypeptide antibiotics.,Ophthalmic use in eyes with corneal abrasions or perforation (relative).,Known history of neomycin-associated ototoxicity or nephrotoxicity.
No significant food interactions. No dietary restrictions required.
No significant food interactions; topical application minimizes systemic absorption. No dietary restrictions.
Teratogenic risk is minimal due to negligible systemic absorption from topical application. No studies report fetal harm from bacitracin, neomycin, polymyxin B, or hydrocortisone acetate when used topically. Avoid prolonged use of high-dose hydrocortisone during first trimester due to potential corticosteroid effects.
Bacitracin-Neomycin-Polymyxin is a topical combination with negligible systemic absorption; thus, fetal risk is minimal. No known teratogenic effects reported; animal studies for individual components show no fetal harm at systemic doses. However, neomycin has theoretical risk of ototoxicity if systemically absorbed, but topical use is considered low risk. FDA Pregnancy Category C for components, but topical use deemed safe.
Systemic absorption is minimal; topical application likely poses low risk to nursing infant. M/P ratio not established for the combination. Avoid application to breast area to prevent infant ingestion.
Minimal systemic absorption after topical application; excretion into breast milk is unlikely. M/P ratio not determined; safe for use during breastfeeding if applied to small areas and not to open wounds.
No dose adjustment required for topical application during pregnancy. Use sparingly on limited areas to minimize systemic absorption.
No dosing adjustments necessary for pregnancy. Pharmacokinetic changes due to pregnancy (e.g., increased skin blood flow, hydration) are not clinically significant for this topical combination. Standard topical application is appropriate.
This combination product is used for otitis externa and certain ophthalmic infections. The hydrocortisone reduces inflammation, but can mask signs of fungal or viral superinfection. Avoid use in patients with tympanic membrane perforation due to risk of ototoxicity from neomycin and polymyxin B. Neomycin carries sensitization risk; prolonged use may cause contact dermatitis. Monitor for overgrowth of non-susceptible organisms when used beyond 10 days.
Triple antibiotic ointment (bactiracin-neomycin-polymyxin) is first-line for prophylaxis of minor skin infections; avoid use on large areas, deep wounds, or burns due to risk of systemic absorption and nephrotoxicity. Neomycin carries high risk of allergic contact dermatitis; consider alternative in patients with known hypersensitivity. Topical use only; not for ophthalmic or intranasal application due to polymyxin ocular toxicity. Synergistic coverage includes Gram-positive (bacitracin), Gram-negative (polymyxin), and broad-spectrum (neomycin).
Use exactly as prescribed; do not exceed recommended duration.,Avoid contact with eyes unless specifically directed for ophthalmic use.,Do not use if you have a perforated eardrum or ear discharge.,Stop use and notify your doctor if symptoms worsen or persist after 10 days.,Inform your doctor if you experience new pain, redness, or swelling.,Keep this medication out of reach of children.
Apply a thin layer to clean, minor cuts, scrapes, or burns 1-3 times daily.,Do not use on large body areas, deep puncture wounds, animal bites, or serious burns.,Stop use and consult doctor if rash, irritation, or signs of infection (worsening redness, swelling, pus) develop.,Avoid use on eyes, nose, or mouth; if contact occurs, rinse thoroughly with water.,Tell your doctor if you have kidney problems or are allergic to any of the ingredients (bacitracin, neomycin, polymyxin B).
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacitracin."
"Bacitracin may increase the nephrotoxic activities of Colistimethate."
"Bacitracin may increase the nephrotoxic activities of Streptomycin."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE vs BACITRACIN-NEOMYCIN-POLYMYXIN, answered by our medical review team.
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is a Aminoglycoside Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of m RNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.. BACITRACIN-NEOMYCIN-POLYMYXIN is a Aminoglycoside Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE and BACITRACIN-NEOMYCIN-POLYMYXIN depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is: Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.. The standard adult dose of BACITRACIN-NEOMYCIN-POLYMYXIN is: Apply topically to affected area 2-5 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE and BACITRACIN-NEOMYCIN-POLYMYXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is classified as Category A/B. Teratogenic risk is minimal due to negligible systemic absorption from topical application. No studies report fetal harm from bacitracin, neomycin, polymyxin B, or hydrocortisone a. BACITRACIN-NEOMYCIN-POLYMYXIN is classified as Category A/B. Bacitracin-Neomycin-Polymyxin is a topical combination with negligible systemic absorption; thus, fetal risk is minimal. No known teratogenic effects reported; animal studies for i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.